Frigo Daniel E, Bondesson Maria, Williams Cecilia
Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
Essays Biochem. 2021 Dec 17;65(6):847-856. doi: 10.1042/EBC20210020.
Nuclear receptors are classically defined as ligand-activated transcription factors that regulate key functions in reproduction, development, and physiology. Humans have 48 nuclear receptors, which when dysregulated are often linked to diseases. Because most nuclear receptors can be selectively activated or inactivated by small molecules, they are prominent therapeutic targets. The basic understanding of this family of transcription factors was accelerated in the 1980s upon the cloning of the first hormone receptors. During the next 20 years, a deep understanding of hormone signaling was achieved that has translated to numerous clinical applications, such as the development of standard-of-care endocrine therapies for hormonally driven breast and prostate cancers. A 2004 issue of this journal reviewed progress on elucidating the structures of nuclear receptors and their mechanisms of action. In the current issue, we focus on the broad application of new knowledge in this field for therapy across diverse disease states including cancer, cardiovascular disease, various inflammatory diseases, the aging brain, and COVID-19.
核受体传统上被定义为配体激活的转录因子,可调节生殖、发育和生理过程中的关键功能。人类有48种核受体,当它们失调时,往往与疾病有关。由于大多数核受体可以被小分子选择性激活或失活,它们是重要的治疗靶点。20世纪80年代,随着首个激素受体的克隆,对这一家族转录因子的基本认识得到了加速。在接下来的20年里,人们对激素信号传导有了深入的了解,并已转化为众多临床应用,例如针对激素驱动的乳腺癌和前列腺癌开发了标准的内分泌治疗方法。该杂志2004年的一期回顾了阐明核受体结构及其作用机制方面的进展。在本期中,我们重点关注该领域新知识在多种疾病状态治疗中的广泛应用,包括癌症、心血管疾病、各种炎症性疾病、衰老大脑和新冠肺炎。